Skip to content

PHARMACHON • JUNE 16-18 • CHICAGO, IL

About
Achondroplasia
- Studies and Trials
Pharmachon
News

IMG_2352

Posted @withregram • @fundacionalpe Empieza @pha

Posted @withregram • @fundacionalpe Empieza @pharmachon con interesantes charlas sobre los temas de más interés que se están estudiando actualmente;ensayos clínicos, cirugía y manejo de la acondroplasia han sidos los más relevantes.
El Dr. Ravib Savarirayan unos de los mayores expertos en acondroplasia y miembro de nuestro comité científico ha sido el encargado de abrir la jornada.
#fudacionalpe
#achondroplasia
#research
#adee
#acondroplasia
#investigación

—
This event is brought to you by the @chandlerproject and sponsored & supported by:
@biomarinpharmaceutical
#QEDtherapeutics
#TyraBiosciences
#AscendisPharma
@pfizerinc

#PHARMACHON #AchondroplasiaResearch #AchondroplasiaAwareness #AchondroplasiaCommunity #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #DwarfismCommunity #SkeletalDysplasia #PatientAdvocacy #PatientAdvocate #PatientCommunity

Posted @withregram • @fundacionalpe La fundació

Posted @withregram • @fundacionalpe La fundación ALPE participa en @pharmachon , congreso organizado por @chandlerproject , que reune a los principales laboratorios que tienen ensayos clínicos para la acondroplasia o como el caso de la farmaceútica biomarin ya tienen fármacos en el mercado.
Susana y Fani han viajado hasta Chicago para recoger toda la actualización sobre la investigación y para llevar a cabo una representación activa de las necesidades de las familias.
Os mantendremos informados de toda la actualildad.
#fundacionalpe
#research
#achondroplasia
@pharmachon

—
This event is brought to you by the @chandlerproject and sponsored & supported by:
@biomarinpharmaceutical
#QEDtherapeutics
#TyraBiosciences
#AscendisPharma
@pfizerinc

#PHARMACHON #AchondroplasiaResearch #AchondroplasiaAwareness #AchondroplasiaCommunity #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #DwarfismCommunity #SkeletalDysplasia #PatientAdvocacy #PatientAdvocate #PatientCommunity

Posted @withregram • @asociacionaconar 🏙️En

Posted @withregram • @asociacionaconar 🏙️En Chicago, médicos y laboratorios expusieron los avances científicos en relación a la acondroplasia y las displasias esqueléticas que causan enanismo. 🙋‍♀️ACONAR estuvo presente para aprender, compartir ideas, y analizar realidades diferentes. 👉🏽A nuestro regreso compartiremos las novedades mas sobresalientes. 🦋Gracias @chandlerproject por recibirnos tan calidamente en esta hermosa ciudad. @pharmachon #acondroplasia #achondroplasiaresearch #achondroplasia #aconar #adee #acondroplasiainvestigacion #calidaddevida #accesomedicamentos #accesotratamientos

—
This event is brought to you by the @chandlerproject and sponsored & supported by:
@biomarinpharmaceutical
#QEDtherapeutics
#TyraBiosciences
#AscendisPharma
@pfizerinc

#PHARMACHON #AchondroplasiaAwareness #AchondroplasiaCommunity #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #DwarfismCommunity #SkeletalDysplasia #PatientAdvocacy #PatientAdvocate #PatientCommunity

Posted @withregram • @asociacionaconar 🤝Hoy e

Posted @withregram • @asociacionaconar 🤝Hoy en la Conferencia Pharmachon compartimos con otras organizaciones experiencias e inquietudes en relación a las ADEE. 💪🏻Definitivamente queda mucho trabajo por hacer hacia un diagnostico preciso y humanizado, un efectivo seguimiento de la salud por un equipo multidisciplinario y con experiencia durante toda la vida, acceso equitativo a nuevos tratamientos, mejorar la calidad de vida y abogar por el respeto de los derechos y la dignidad de las personas con ADEE y su participacion plena y efectiva en la sociedad en igualdad de condiciones con todos los demás. @pequenaspersonaslatinas_ @instituto.nacional.nanismo @chancrews @fundacionalpe @chandlerproject @pharmachon

—
This event is brought to you by the @chandlerproject and sponsored & supported by:
@biomarinpharmaceutical
#QEDtherapeutics
#TyraBiosciences
#AscendisPharma
@pfizerinc

#PHARMACHON #AchondroplasiaResearch #AchondroplasiaAwareness #AchondroplasiaCommunity #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #DwarfismCommunity #SkeletalDysplasia #PatientAdvocacy #PatientAdvocate #PatientCommunity

John Caminis, M.D. will be presenting ‘Introduct

John Caminis, M.D. will be presenting ‘Introduction of #AscendisPharma’ and #TransCon Technology at #PHARMACHON

John Caminis, M.D. is the U.S. Head of Medical Strategy and Engagement and part of the senior management team in Medical Affairs at #Ascendis Pharma. Before joining Ascendis Pharma, Dr. Caminis was as at Radius Health where he served as Head of Integrated Evidence & Medical Strategy. Dr. Caminis’ experience ranges from small biotech to major pharmaceutical companies with expertise in clinical, medical, regulatory, and commercialization as well as a wide spectrum of diseases and indications. Prior to Radius Health, Dr. Caminis held several roles of increasing responsibility at Sanofi beginning as Therapeutic Area Strategy lead, Safety TA Head for Rare Disease, and followed by TA head of Immunology. Dr. Caminis has also served in roles of increasing responsibility at Baxter, Baxalta, Shire, Takeda, and prior to that has been part of UCB, Novartis, and Roche.

#AchondroplasiaResearch #AchondroplasiaAwareness #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #SkeletalDysplasia #Pediatrics #Peds #Endocrine #Endocrinology #ENDO2023

#AscendisPharma is gold sponsor of #PHARMACHON #A

#AscendisPharma is gold sponsor of #PHARMACHON

#Ascendis is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by their core values of patients, science and passion, they use their TransCon® technology to fulfill their mission of developing new and potentially best-in-class therapies that address unmet medical needs.

To learn more about Ascendis, visit AscendisPharma.com

#AchondroplasiaResearch #AchondroplasiaAwareness #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #SkeletalDysplasia #Pediatrics #Peds #Endocrine #TransConCNP

Ronald Swanson is Chief Scientific Officer of #Tyr

Ronald Swanson is Chief Scientific Officer of #TyraBiosciences. At #PHARMACHON, he will present #TYRA300, an #FGFR3 Inhibitor.

TYRA is a platinum sponsor of this event.

#AchondroplasiaResearch #AchondroplasiaAwareness #TreatingAchondroplasia #Dwarfism #DwarfismAwareness #SkeletalDysplasia #Pediatrics #Peds

#TyraBiosciences is a platinum sponsor of #PHARMAC

#TyraBiosciences is a platinum sponsor of #PHARMACHON.

Earlier this spring, Tyra announced the expansion of development of #TYRA300.

According to TYRA, “We are developing TYRA-300 to address long-term complications and improve quality of life in affected individuals with skeletal dysplasias including achondroplasia, a genetic condition caused by a mutation in the FGFR3 gene.
Our drug discovery efforts are driven by structural insights informed by hundreds of internally solved FGFR crystal structures. The TYRA-300 (ACH) program is in the IND-enabling stage.”

To learn more about TYRA, visit tyra.bio

#AchondroplasiaResearch #AchondroplasiaAwareness #TreatingAchondroplasia #FGFR3 #Dwarfism #DwarfismAwareness #SkeletalDysplasia

Copyright © 2023 · The Chandler Project · Hello You Designs

About
Achondroplasia
- Studies and Trials
Pharmachon
News

Search for: